GlobeNewsWire
24 Jun 2026, 10:35 UTC · 13w ago
Verdict
Headline takes no side. We score ABSI +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Eli Lilly & Company is participating in a $100 million equity offering for Absci Corporation.
More positive than 92% of claims this week
Absci is pricing an underwritten offering of approximately 13.5 million shares at $7.41 per share.
So whatEquity offerings typically cause immediate share price dilution for existing stockholders.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 78% of claims this week
Net proceeds from the offering will be used to advance the ABS-201 anti-PRLR antibody program for androgenetic alopecia and endometriosis.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company successfully priced a $100 million offering to fund the advancement of its AI-designed antibody program.
More positive than 52% of ticker scores this week
Eli Lilly is participating as an investor in Absci's capital raise, signaling strategic interest in AI-driven drug discovery.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+31.5%
Price agrees with the score
$9.74 vs $7.41 close before publication (Jun 23) · not market-adjusted
ABSI chart →
